This factor is crucial for melanoma resistance to BRAF and MEK inhibitors, which is associated with increased levels of CD20 and IGF-1 mRNA in tumors and IGF-1 expression in tumor-associated B lymphocytes. This evidence concerns the gene IGF1 and neoplasm.